Table 4

PRMT5 expression in NET
Cytoplasmic high PRMT5, n (%) P Nuclear high PRMT5, n (%) P Na
Age ≤60 years (n = 59) 8 (6.3) 0.43 12 (9.4) 0.61 128
>60 years (n = 69) 12 (9.4) 19 (14.8)
Gender Female (n = 62) 7 (5.4) 0.33 18 (14.0) 0.16 129
Male (n = 67) 14 (10.9) 13 (10.1)
Size ≤3 cm (n = 69) 9 (8.3) 0.71 19 (17.6) 0.76 108
>3 cm (n = 39) 7 (6.5) 11 (10.2)
Stage I (n = 69) 12 (12.0) 0.48 17 (17.0) 0.42 100
II-IV (n = 31) 7 (7.0) 10 (10.0)
Histology Carcinoid (n = 63) 6 (4.5) 0.04 22 (16.5) 0.02 133
HG-NET (n = 70) 16 (12.0) 10 (7.5)
Survival Yes (n = 46) 8 (8.0) 0.923 16 (16.0) 0.02 100
No (n = 54) 9 (9.0) 8 (8.0)

Abbreviations: Neg negative, N number of cases, HG-NET high grade neuroendocrine tumors.

aReflects total number of cases with available annotations.

Shilo et al.

Shilo et al. Diagnostic Pathology 2013 8:201   doi:10.1186/1746-1596-8-201

Open Data